Clinical Trial Update: Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of flotetuzumab for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Flotetuzumab (flotetuzumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Relapsed Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2024-12-06